Literature DB >> 24914372

miR-132 inhibits colorectal cancer invasion and metastasis via directly targeting ZEB2.

Yong-Bin Zheng1, Hai-Ping Luo1, Qiang Shi1, Zhi-Nan Hao1, Yu Ding1, Qiu-Shuang Wang1, Sheng-Bo Li1, Gao-Chun Xiao1, Shi-Lun Tong1.   

Abstract

AIM: To investigate the biological role and underlying mechanism of miR-132 in colorectal cancer (CRC) progression and invasion.
METHODS: Quantitative RT-PCR analysis was used to examine the expression levels of miR-132 in five CRC cell lines (SW480, SW620, HCT116, HT29 and LoVo) and a normal colonic cell line NCM460, as well as in tumor tissues with or without metastases. The Kaplan-Meier method was used to analyze the prognostic significance of miR-132 in CRC patients. The biological effects of miR-132 were assessed in CRC cell lines using the transwell assay. Quantitative RT-PCR and western blot analyses were employed to evaluate the expression of miR-132 targets. The regulation of ZEB2 by miR-132 was confirmed using the luciferase activity assay.
RESULTS: miR-132 was significantly down-regulated in the CRC cell lines compared with the normal colonic cell line (P < 0.05), as well as in the CRC tissues with distant metastases compared with the tissues without metastases (10.52 ± 4.69 vs 23.11 ± 7.84) (P < 0.001). Down-regulation of miR-132 was associated with tumor size (P = 0.016), distant metastasis (P = 0.002), and TNM stage (P = 0.020) in CRC patients. Kaplan-Meier survival curve analysis indicated that patients with low expression of miR-132 tended to have worse disease-free survival than patients with high expression of miR-132 (P < 0.001). Moreover, ectopic expression of miR-132 markedly inhibited cell invasion (P < 0.05) and the epithelial-mesenchymal transition (EMT) in CRC cell lines. Further investigation revealed ZEB2, an EMT regulator, was a downstream target of miR-132.
CONCLUSION: Our study indicated that miR-132 plays an important role in the invasion and metastasis of CRC.

Entities:  

Keywords:  Colorectal cancer; Epithelial-mesenchymal transition; Invasion; Metastasis; MicroRNA; Prognosis; miR-132

Mesh:

Substances:

Year:  2014        PMID: 24914372      PMCID: PMC4047336          DOI: 10.3748/wjg.v20.i21.6515

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

1.  MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2).

Authors:  Nicola Valeri; Pierluigi Gasparini; Chiara Braconi; Alessio Paone; Francesca Lovat; Muller Fabbri; Khlea M Sumani; Hansjuerg Alder; Dino Amadori; Tushar Patel; Gerard J Nuovo; Richard Fishel; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

2.  DNA methylation silences miR-132 in prostate cancer.

Authors:  A Formosa; A M Lena; E K Markert; S Cortelli; R Miano; A Mauriello; N Croce; J Vandesompele; P Mestdagh; E Finazzi-Agrò; A J Levine; G Melino; S Bernardini; E Candi
Journal:  Oncogene       Date:  2012-02-06       Impact factor: 9.867

3.  Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells.

Authors:  Maria I Almeida; Milena S Nicoloso; Lizhi Zeng; Cristina Ivan; Riccardo Spizzo; Roberta Gafà; Lianchun Xiao; Xinna Zhang; Ivan Vannini; Francesca Fanini; Muller Fabbri; Giovanni Lanza; Rui M Reis; Patrick A Zweidler-McKay; George A Calin
Journal:  Gastroenterology       Date:  2012-01-10       Impact factor: 22.682

4.  miR-93 suppresses proliferation and colony formation of human colon cancer stem cells.

Authors:  Xiao-Feng Yu; Jian Zou; Zhi-Jun Bao; Jie Dong
Journal:  World J Gastroenterol       Date:  2011-11-14       Impact factor: 5.742

5.  Hsa-miR-132 regulates apoptosis in non-small cell lung cancer independent of acetylcholinesterase.

Authors:  Bo Zhang; Lu Lu; Xuejin Zhang; Weiyuan Ye; Jun Wu; Qiliang Xi; Xuejun Zhang
Journal:  J Mol Neurosci       Date:  2013-10-26       Impact factor: 3.444

6.  miRNA-132 orchestrates chromatin remodeling and translational control of the circadian clock.

Authors:  Matías Alvarez-Saavedra; Ghadi Antoun; Akiko Yanagiya; Reynaldo Oliva-Hernandez; Daniel Cornejo-Palma; Carolina Perez-Iratxeta; Nahum Sonenberg; Hai-Ying M Cheng
Journal:  Hum Mol Genet       Date:  2010-11-30       Impact factor: 6.150

7.  Epigenetic repression of miR-132 expression by the hepatitis B virus x protein in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Xufu Wei; Cui Tan; Chengyong Tang; Guosheng Ren; Tingxiu Xiang; Zhu Qiu; Rui Liu; Zhongjun Wu
Journal:  Cell Signal       Date:  2013-01-30       Impact factor: 4.315

8.  MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation.

Authors:  Shuai Li; Huimin Meng; Feng Zhou; Lili Zhai; Lina Zhang; Feng Gu; Yu Fan; Ronggang Lang; Li Fu; Lin Gu; Liqiang Qi
Journal:  Pathol Res Pract       Date:  2013-02-08       Impact factor: 3.250

Review 9.  MicroRNA-21 as a potential colon and rectal cancer biomarker.

Authors:  Tao Li; Mei Ha Leong; Bruce Harms; Gregory Kennedy; Lin Chen
Journal:  World J Gastroenterol       Date:  2013-09-14       Impact factor: 5.742

10.  Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF.

Authors:  Sanchita Roy; Edi Levi; Adhip P N Majumdar; Fazlul H Sarkar
Journal:  J Hematol Oncol       Date:  2012-09-19       Impact factor: 17.388

View more
  48 in total

1.  LncRNA SNHG5 affects cell proliferation, metastasis and migration of colorectal cancer through regulating miR-132-3p/CREB5.

Authors:  Mingbao Zhang; Yue Li; Hongbo Wang; Weihua Yu; Sen Lin; Jianqiang Guo
Journal:  Cancer Biol Ther       Date:  2018-11-05       Impact factor: 4.742

2.  Extensive miRNA expression analysis in craniopharyngiomas.

Authors:  Jill Samis; Elio F Vanin; Simone Treiger Sredni; Maria de Fátima de Bonaldo; Fabricio F Costa; Tadanori Tomita; Reema Habiby; Donald Zimmerman; Marcelo B Soares
Journal:  Childs Nerv Syst       Date:  2016-06-07       Impact factor: 1.475

3.  Three-dimensional genome: developmental technologies and applications in precision medicine.

Authors:  Yingqi Li; Tao Tao; Likun Du; Xiao Zhu
Journal:  J Hum Genet       Date:  2020-03-09       Impact factor: 3.172

Review 4.  The outstanding role of miR-132-3p in carcinogenesis of solid tumors.

Authors:  Milad Rafat; Mahta Moraghebi; Masoumeh Afsa; Kianoosh Malekzadeh
Journal:  Hum Cell       Date:  2021-05-17       Impact factor: 4.174

5.  Human thymic stromal lymphopoietin promotes the proliferation and invasion of cervical cancer cells by downregulating microRNA-132 expression.

Authors:  Wen-Jie Zhou; Hui-Li Yang; Kai-Kai Chang; Yi Meng; Ming-Yan Wang; Min-Min Yuan; Ming-Qing Li; Feng Xie
Journal:  Oncol Lett       Date:  2017-10-23       Impact factor: 2.967

6.  MicroRNA-132 suppresses cell proliferation in human breast cancer by directly targeting FOXA1.

Authors:  Dan Wang; Jin Ren; Hui Ren; Jin-Ling Fu; Dan Yu
Journal:  Acta Pharmacol Sin       Date:  2017-08-17       Impact factor: 6.150

7.  MicroRNA-132 targets PEA-15 and suppresses the progression of astrocytoma in vitro.

Authors:  Fei Geng; Jian-Lin Wu; Gui-Feng Lu; Zhi-Ping Liang; Zhuo-Li Duan; Xi Gu
Journal:  J Neurooncol       Date:  2016-06-13       Impact factor: 4.130

8.  ZEB2 promotes tumor metastasis and correlates with poor prognosis of human colorectal cancer.

Authors:  Ming-Zhe Li; Jing-Jing Wang; Shi-Bin Yang; Wen-Feng Li; Long-Bin Xiao; Yu-Long He; Xin-Ming Song
Journal:  Am J Transl Res       Date:  2017-06-15       Impact factor: 4.060

9.  miR-132 inhibits lung cancer cell migration and invasion by targeting SOX4.

Authors:  Yang Li; Lingling Zu; Yuli Wang; Min Wang; Peirui Chen; Qinghua Zhou
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

Review 10.  Inflammation related miRNAs as an important player between obesity and cancers.

Authors:  Morteza Gholami; Bagher Larijani; Zhila Zahedi; Fatemeh Mahmoudian; Samira Bahrami; Sima Parvizi Omran; Zahra Saadatian; Shirin Hasani-Ranjbar; Reza Taslimi; Milad Bastami; Mahsa M Amoli
Journal:  J Diabetes Metab Disord       Date:  2019-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.